Clinical Trial Delay and Staff Cuts Trigger Sharp Decline for Bolt Biotherapeutics

Strategic Restructuring Extends Financial Runway

Shares of Bolt Biotherapeutics are trading significantly lower following a dual announcement of a major clinical program delay and a substantial workforce reduction. The company revealed that pivotal data for its flagship asset, BDC-4182, will arrive later than anticipated, concurrently disclosing plans to cut its employee base by half to preserve capital. This news precipitated a steep sell-off, erasing more than 16 percent of the stock’s value within a 48-hour period.